Lilly’s Tizepatide Cuts Type 2 Diabetes Risk by 94%, New Data Shows

Lilly’s Tizepatide Cuts Type 2 Diabetes Risk by 94%, New Data Shows …C0NTINUE READING HERE >>>

Eli Lilly shared more good news this week about the health benefits of tirzepatide—the active ingredient in the obesity and diabetes medications Zepbound and Mounjaro.

Early results from a three-year clinical study indicate that the blockbuster GLP-1 medication can not only treat type 2 diabetes but may also prevent the condition in people with prediabetes and obesity or overweight. The clinical trial is the longest finalized study of tirzepatide so far.

Tirzepatide cuts the risk of…

>